Research on bronchiectasis in Chinese patients using genomics and endotyping
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
This study is trying to better understand different types of bronchiectasis in Chinese patients to find out how they respond to treatments and improve personalized care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China Academic / other |
| Locations | 9 sites (Guiyang, Guizhou and 8 other locations) |
| Trial ID | NCT06900062 on ClinicalTrials.gov |
What this trial studies
The C-BRIDGE Study aims to characterize the phenotypes and endotypes of bronchiectasis in Chinese patients, addressing the lack of data specific to this population. By analyzing clinical, genomic, microbiological, and inflammatory factors, the study seeks to identify distinct patient subgroups and their responses to treatment. This observational study will involve patients during stable disease and exacerbations, with the goal of developing personalized medicine strategies based on the findings. The research will also explore specific conditions like allergic bronchopulmonary aspergillosis and primary ciliary dyskinesia to enhance understanding and management of bronchiectasis in China.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with a confirmed diagnosis of bronchiectasis who have been clinically stable for at least four weeks.
Not a fit: Patients under 18 years old or those with active tuberculosis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for bronchiectasis patients in China.
How similar studies have performed: While studies on bronchiectasis have been conducted primarily in European populations, this approach is novel in the context of Chinese patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and/or recurrent respiratory tract infections. * At the screening visit, participants must have been clinically stable for 4 weeks, defined as no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks. Exclusion Criteria: * Inability to provide informed consent * Age under 18 years * Patients with active tuberculosis * Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks
Where this trial is running
Guiyang, Guizhou and 8 other locations
- Lin Liu — Guiyang, Guizhou, China (Recruiting)
- Lei Song — Changchun, Jilin, China (Recruiting)
- Qian Qi — Jinan, Shangdong, China (Recruiting)
- He-feng Chen — Shanghai, Shanghai Municipality, China (Recruiting)
- Zhou-fang Mei — Shanghai, Shanghai Municipality, China (Recruiting)
- Jun She — Shanghai, Shanghai Municipality, China (Recruiting)
- Xue-ling Wu — Shanghai, Shanghai Municipality, China (Recruiting)
- Yong-hua Gao — Shanghai, Shanghai Municipality, China (Recruiting)
- Xiao-long Ma — Jiaxing, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Yong-hua Gao, Ph.D. — Shanghai Pulmonary Hospital, Shanghai, China
- Study coordinator: Yong-hua Gao, Ph.D.
- Email: gaoyonghuahust@163.com
- Phone: +86 17321278520
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.